Meds & supplements › Fluorescein
Medicine
For testing tear film stability by determining the fluorescein break-up time (FBUT).
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.
The following serious ocular adverse reactions are described elsewhere in the labeling:
The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product.
Instill 1 to 2 drops topically in the eye as needed.
sofidex [Internet]. Daloreum; c2026. Fluorescein; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/fluorescein
sofidex. (2026, August 2). Fluorescein. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/fluorescein
Fluorescein. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/fluorescein
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.